NO20041186L - Diagnostiske eller terapeutiske somatostatin- eller bombesinanalogkonjugater og anvendelser derav - Google Patents

Diagnostiske eller terapeutiske somatostatin- eller bombesinanalogkonjugater og anvendelser derav

Info

Publication number: NO20041186L
Authority: NO; Norway
Prior art keywords: diagnostic; bombesin analog; analog conjugates; therapeutic somatostatin; somatostatin
Prior art date: 2001-09-21

Application number

NO20041186A

Other languages

English (en)

Norwegian (no)

Inventor

William Andrew Murphy

David H Coy

Joseph A Fuselier

Sun Lichun

Original Assignee

Univ Tulane

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-09-21

Filing date

2004-03-22

Publication date

2004-05-05

2004-03-22 Application filed by Univ Tulane filed Critical Univ Tulane

2004-05-05 Publication of NO20041186L publication Critical patent/NO20041186L/no

Links

102000005157 Somatostatin Human genes 0.000 title 1
108010056088 Somatostatin Proteins 0.000 title 1
DNDCVAGJPBKION-DOPDSADYSA-N bombesin Chemical class C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(N)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC=1NC2=CC=CC=C2C=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1NC(=O)CC1)C(C)C)C1=CN=CN1 DNDCVAGJPBKION-DOPDSADYSA-N 0.000 title 1
NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 title 1
229960000553 somatostatin Drugs 0.000 title 1
230000001225 therapeutic effect Effects 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/083—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins the peptide being octreotide or a somatostatin-receptor-binding peptide
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Epidemiology (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Optics & Photonics (AREA)
Physics & Mathematics (AREA)
Molecular Biology (AREA)
Neurology (AREA)
Urology & Nephrology (AREA)
Ophthalmology & Optometry (AREA)
Biomedical Technology (AREA)
Heart & Thoracic Surgery (AREA)
Neurosurgery (AREA)
Gastroenterology & Hepatology (AREA)
Immunology (AREA)
Cardiology (AREA)
Pulmonology (AREA)
Endocrinology (AREA)
Reproductive Health (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Peptides Or Proteins (AREA)
Medicinal Preparation (AREA)
Percussion Or Vibration Massage (AREA)

NO20041186A 2001-09-21 2004-03-22 Diagnostiske eller terapeutiske somatostatin- eller bombesinanalogkonjugater og anvendelser derav NO20041186L (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US32385101P	2001-09-21	2001-09-21
PCT/US2002/030143 WO2003028527A2 (en)	2001-09-21	2002-09-20	Diagnostic or therapeutic somatostatin or bombesin analog conjugates and uses thereof

Publications (1)

Publication Number	Publication Date
NO20041186L true NO20041186L (no)	2004-05-05

Family

ID=23260992

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20041186A NO20041186L (no)	2001-09-21	2004-03-22	Diagnostiske eller terapeutiske somatostatin- eller bombesinanalogkonjugater og anvendelser derav

Country Status (16)

Country	Link
US (1)	US7326685B2 (is)
EP (1)	EP1435826A4 (is)
JP (1)	JP4799820B2 (is)
KR (1)	KR20040047846A (is)
CN (1)	CN1589151A (is)
AU (1)	AU2002341792B2 (is)
BR (1)	BR0212897A (is)
CA (1)	CA2461099A1 (is)
IL (2)	IL160993A0 (is)
IS (1)	IS7189A (is)
MX (1)	MXPA04002621A (is)
NO (1)	NO20041186L (is)
NZ (1)	NZ532204A (is)
PL (1)	PL369336A1 (is)
WO (1)	WO2003028527A2 (is)
ZA (1)	ZA200402698B (is)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6721705B2 (en) *	2000-02-04	2004-04-13	Webley Systems, Inc.	Robust voice browser system and voice activated device controller
MXPA04008419A (es)	2002-03-01	2004-11-26	Univ Tulane	Conjugados de agentes terapeuticos o citotoxicos y peptidos biologicamente activos.
US8060626B2 (en) *	2008-09-22	2011-11-15	Sony Computer Entertainment America Llc.	Method for host selection based on discovered NAT type
US7977049B2 (en) *	2002-08-09	2011-07-12	President And Fellows Of Harvard College	Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms
EP1624884A4 (en) *	2003-04-22	2009-08-05	Ipsen Pharma	SOMATOSTATIN VECTORS
EP2236131A3 (en) *	2003-07-01	2011-03-02	President and Fellows of Harvard College	Sirt1 modulators for manipulating cell/organism lifespan/stress response
US20060025337A1 (en) *	2003-07-01	2006-02-02	President And Fellows Of Harvard College	Sirtuin related therapeutics and diagnostics for neurodegenerative diseases
JP2007527418A (ja)	2003-12-29	2007-09-27	プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ	肥満及びインシュリン耐性障害を治療又は防止するための組成物
US8017634B2 (en) *	2003-12-29	2011-09-13	President And Fellows Of Harvard College	Compositions for treating obesity and insulin resistance disorders
US20050255045A1 (en) *	2004-05-13	2005-11-17	Woltering Eugene A	Surgical marking composition and method
CA2467321A1 (en) *	2004-05-14	2005-11-14	Paul J. Santerre	Polymeric coupling agents and pharmaceutically-active polymers made therefrom
EP1744787A4 (en) *	2004-05-14	2011-04-06	Interface Biologics Inc	POLYMER COUPLING AGENTS AND PHARMACEUTICALLY ACTIVE POLYMERS MANUFACTURED THEREOF
EP1765316A2 (en) *	2004-06-16	2007-03-28	The President and Fellows of Harvard College	Methods and compositions for modulating bax-ku70-mediated apoptosis
US20060014705A1 (en) *	2004-06-30	2006-01-19	Howitz Konrad T	Compositions and methods for selectively activating human sirtuins
WO2006138418A2 (en) *	2005-06-14	2006-12-28	President And Fellows Of Harvard College	Improvement of cognitive performance with sirtuin activators
AU2006259261B2 (en) *	2005-06-16	2013-06-13	Myrexis, Inc.	Pharmaceutical compositions and use thereof
EP1987846B1 (en) *	2006-02-23	2016-07-13	Adeka Corporation	Diagnostic marker
DE102006035083A1 (de) *	2006-07-28	2008-01-31	medac Gesellschaft für klinische Spezialgeräte mbH	Proteinbindende Methotrexat-Derivate und diese enthaltende Arzneimittel
PL2076535T3 (pl)	2006-10-16	2013-08-30	Salk Inst Biological Studies	Antagoniści somatostatyny selektywni względem receptora (SSTR2)
US8691761B2 (en)	2006-10-16	2014-04-08	Jean E. F. Rivier	Somatostatin receptor 2 antagonists
RU2457218C2 (ru) *	2006-10-20	2012-07-27	Ипсен Фарма С.А.С.	Конъюгаты цитотоксических средств с пептидами
CA2720989A1 (en) *	2007-04-10	2008-10-16	Myrexis, Inc.	Methods for treating cancer
WO2008124824A1 (en) *	2007-04-10	2008-10-16	Myriad Genetics, Inc.	Dosages and methods for the treatment of cancer
WO2008124828A1 (en) *	2007-04-10	2008-10-16	Myriad Genetics, Inc.	Methods for treating vascular disruption disorders
AU2008236994A1 (en) *	2007-04-10	2008-10-16	Myrexis, Inc.	Method of treating melanoma
AU2008236993A1 (en) *	2007-04-10	2008-10-16	Myrexis, Inc.	Method of treating brain cancer
CN108514638A (zh)	2011-02-17	2018-09-11	杜兰教育基金委员会	多组分组合物以及它们的用途
US10351626B2 (en)	2013-03-14	2019-07-16	The Scripps Research Institute	Targeting agent antibody conjugates and uses thereof
JP6951826B2 (ja)	2016-02-04	2021-10-20	ザスクリプスリサーチインスティテュート	ヒト化抗ｃｄ３抗体、その複合体、およびその使用
WO2017136943A1 (en)	2016-02-09	2017-08-17	Cdrd Ventures Inc.	Somatostatin receptor antagonist compounds and methods of using the same
AU2017238246B2 (en)	2016-03-24	2021-04-01	The Administrators Of The Tulane Educational Fund	Conjugates of tacrolimus, their compositions, and their uses
US12485191B2 (en) *	2017-11-28	2025-12-02	Board Of Regents Of The Univeristy Of Nebraska	Radiopharmaceuticals and methods of use thereof
CA3087898A1 (en)	2018-02-02	2019-08-08	Ripple Therapeutics Corporation	Glass formulations comprising steroid dimers and uses thereof
AU2019234523B2 (en) *	2018-03-15	2024-09-12	Osaka University	Pharmaceutical composition containing 211At-labeled amino acid derivative, and method for producing said pharmaceutical composition
WO2020154815A1 (en)	2019-02-01	2020-08-06	Ripple Therapeutics Corporation	Crystalline forms of dexamethasone dimers and uses thereof
US12509469B2 (en)	2019-08-07	2025-12-30	Ripple Therapeutics Corporation	Compositions and methods for the treatment of pain and dependence disorders
JP2023524494A (ja)	2020-05-01	2023-06-12	リップルセラピューティクスコーポレーション	眼障害を処置するためのヘテロ二量体組成物と方法

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4904642A (en)	1985-09-12	1990-02-27	The Administrators Of The Tulane Educational Fund	Therapeutic somatostatin analogs
US4812590A (en)	1987-06-25	1989-03-14	Merck & Co., Inc.	Carbamates of 4-hydroxyanisole as prodrugs for chemotherapy of melanoma
US5073541A (en)	1987-11-18	1991-12-17	Administrators Of The Tulane Educational Fund	Treatment of small cell lung cancer with somatostatin analogs
US5753627A (en)	1988-12-05	1998-05-19	Novartis Ag	Use of certain complexed somatostatin peptides for the invivo imaging of somatostatin receptor-positive tumors and metastasis
US5633263A (en)	1989-04-26	1997-05-27	The Administrators Of The Tulane Educational Fund	Linear somatostatin analogs
DK0436005T3 (da)	1989-07-20	1995-07-03	Sandoz Ltd	Mærkede polypeptidderivater
DK0450480T3 (da) *	1990-04-06	1995-08-14	Univ Tulane	Somatostatinaloger
US5443815A (en)	1991-11-27	1995-08-22	Diatech, Inc.	Technetium-99m labeled peptides for imaging
US5411943A (en)	1992-02-25	1995-05-02	Biomeasure, Inc.	Hepatoma treatment with somatostatin analogs
US5620675A (en)	1992-06-23	1997-04-15	Diatech, Inc.	Radioactive peptides
US5597894A (en) *	1995-06-05	1997-01-28	The Louisiana State University Medical Center Foundation	Multi-tyrosinated somatostatin analogs
US6051554A (en) *	1995-06-07	2000-04-18	Peptor Limited	Conformationally constrained backbone cyclized somatostatin analogs
US5770687A (en)	1995-06-07	1998-06-23	Peptor Limited	Comformationally constrained backbone cyclized somatostatin analogs
US5708135A (en)	1995-09-29	1998-01-13	Biomeasure Incorporated	Cyclic peptide analogs of somatostatin
US5750499A (en)	1995-10-18	1998-05-12	The Salk Institute For Biological Studies	Receptor-selective somatostatin analogs
US5843903A (en)	1995-11-27	1998-12-01	The Administrators Of The Tulane Educational Fund	Targeted cytotoxic anthracycline analogs
US6156725A (en) *	1996-08-16	2000-12-05	National Institute Of Immunology	Drug for the treatment of cancer
JP2002506424A (ja)	1997-04-22	2002-02-26	キュレイターオブザユニバーシィティオブミズーリ	ガストリン受容体−親和性ペプチド結合体
AU4267700A (en) *	2000-01-13	2001-07-19	Academia Sinica	Application of somatostatin analogs to specific delivery of anti-tumor drugs into tumor cells
CN101481405A (zh) *	2001-06-08	2009-07-15	研究及应用科学协会股份有限公司	生长激素释放抑制因子-多巴胺嵌合类似物

2002
- 2002-09-20 CN CNA028230817A patent/CN1589151A/zh active Pending
- 2002-09-20 CA CA002461099A patent/CA2461099A1/en not_active Abandoned
- 2002-09-20 NZ NZ532204A patent/NZ532204A/en not_active IP Right Cessation
- 2002-09-20 US US10/490,326 patent/US7326685B2/en not_active Expired - Fee Related
- 2002-09-20 JP JP2003531872A patent/JP4799820B2/ja not_active Expired - Fee Related
- 2002-09-20 MX MXPA04002621A patent/MXPA04002621A/es active IP Right Grant
- 2002-09-20 PL PL02369336A patent/PL369336A1/xx not_active Application Discontinuation
- 2002-09-20 BR BR0212897-7A patent/BR0212897A/pt not_active IP Right Cessation
- 2002-09-20 AU AU2002341792A patent/AU2002341792B2/en not_active Ceased
- 2002-09-20 IL IL16099302A patent/IL160993A0/xx unknown
- 2002-09-20 EP EP02775944A patent/EP1435826A4/en not_active Withdrawn
- 2002-09-20 KR KR10-2004-7004173A patent/KR20040047846A/ko not_active Ceased
- 2002-09-20 WO PCT/US2002/030143 patent/WO2003028527A2/en not_active Ceased
2004
- 2004-03-19 IS IS7189A patent/IS7189A/is unknown
- 2004-03-21 IL IL160993A patent/IL160993A/en not_active IP Right Cessation
- 2004-03-22 NO NO20041186A patent/NO20041186L/no not_active Application Discontinuation
- 2004-04-06 ZA ZA200402698A patent/ZA200402698B/en unknown

Also Published As

Publication number	Publication date
AU2002341792B2 (en)	2007-09-06
ZA200402698B (en)	2005-04-25
WO2003028527A8 (en)	2004-04-15
CN1589151A (zh)	2005-03-02
IS7189A (is)	2004-03-19
BR0212897A (pt)	2004-08-24
WO2003028527A2 (en)	2003-04-10
MXPA04002621A (es)	2004-07-08
IL160993A0 (en)	2004-08-31
US7326685B2 (en)	2008-02-05
PL369336A1 (en)	2005-04-18
EP1435826A4 (en)	2009-07-15
JP2005505580A (ja)	2005-02-24
WO2003028527A3 (en)	2003-10-30
KR20040047846A (ko)	2004-06-05
EP1435826A2 (en)	2004-07-14
IL160993A (en)	2011-04-28
NZ532204A (en)	2006-04-28
US20050070470A1 (en)	2005-03-31
JP4799820B2 (ja)	2011-10-26
CA2461099A1 (en)	2003-04-10

Legal Events

Date	Code	Title	Description
2012-04-30	FC2A	Withdrawal, rejection or dismissal of laid open patent application

Publication	Publication Date	Title
NO20041186L (no)	2004-05-05	Diagnostiske eller terapeutiske somatostatin- eller bombesinanalogkonjugater og anvendelser derav
DK1404809T3 (da)	2014-03-17	Forbedrede hudsubstitutter og anvendelser deraf
DK2336167T3 (da)	2019-09-02	MHC-molekylkonstrukter og deres anvendelse til diagnose og terapi
NO20040246L (no)	2004-04-01	TACI'er- og BR3-polypeptider og anvendelser derav
DK1417175T3 (da)	2013-10-28	Substituerede dihydro-3-halo-1h-pyrazol-5-carboxylater og fremstillingog anvendelse heraf
NO20044192L (no)	2004-10-04	17alfa-alkyl-17beta-oksy-ostratriener og farmasoytiske preparater
DE10295851T1 (de)	2003-12-24	Dachfensterbaueinheit und Einzelteile
NO20014560D0 (no)	2001-09-19	Quinasoliner og terapautisk anvendelse derav
DE60235204D1 (de)	2010-03-11	Medizinische leitung und leitungsverbindungssystem
AU2003228445A8 (en)	2003-10-27	Tissue composites and uses thereof
NO20030832L (no)	2003-04-22	Kondenserte sykliske forbindelser og medisinsk anvendelse derav
DK1329456T3 (da)	2006-12-04	Glucopyranosyloxybenzylbenzenderivater og medicinske sammensætninger indeholdende samme
EP1545599A4 (en)	2006-04-05	IMMUNOGENIC COMPOSITIONS AND ITS DIAGNOSTIC AND THERAPEUTIC USES
DE60209310D1 (de)	2006-04-27	Aliphatishe Polyesterzusammensetzung und biegsame Erzeugnisse
DE60205718D1 (de)	2005-09-29	Flexibler wellschlauch und anschlussverfahren
EP1572741A4 (en)	2006-09-27	DIAGNOSTIC AND THERAPEUTIC AGENTS
IS7577A (is)	2004-12-01	Arómatísk súlfón og læknisfræðileg notkun þeirra
AU2002303261A8 (en)	2006-11-02	Gene brcc2 and diagnostic and therapeutic uses thereof
IS2841B (is)	2013-08-15	Samstæða hluta og lyfjasamsetningar
NO20033123L (no)	2003-09-03	Terapeutisk hinne dannende sammensetning og behandlingsplan derav
DK1417189T3 (da)	2006-05-08	Acylaminothiazolderivater, fremstilling og terapeutisk anvendelse heraf
EP1462455A4 (en)	2008-12-31	NOVEL PEPTIDES AND THEIR USES AS MEDICAMENTS
DK1556382T3 (da)	2008-10-06	3-Phenylpyridoindolderivater, fremstilling og terapeutisk anvendelse deraf
NO20042693L (no)	2004-08-25	Kateterpreparat og anvendelser derav
FI20021617A0 (fi)	2002-09-10	Diagnostisia ja terapeuttisia menetelmiä